XML 47 R34.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATING BALANCE SHEET AND STATEMENT OF OPERATIONS (Tables)
9 Months Ended
Sep. 30, 2024
CONDENSED CONSOLIDATING BALANCE SHEET AND STATEMENT OF OPERATIONS  
Schedule of condensed consolidating balance sheet

 

 

Yubo

International Biotech

Limited(Parent

 

 

Platinum

(Cayman Islands) and Platinum HK(Cayman

 

 

Yubo

 

 

Yubo Chengdu

 

 

Yubo

Beijing 

(VIE and

 

 

 

 

 

 

 

 

 

Company)

 

 

Island)

 

 

Global

 

 

(WFOE)

 

 

Subsidiaries)

 

 

Eliminations

 

 

Consolidated

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Current Assets

 

$-

 

 

$

 

 

$78,853

 

 

$-

 

 

$645,112

 

 

$-

 

 

$723,965

 

Investment in subsidiaries and variable interest entity (VIE)

 

 

(2,181,987)

 

 

930,000

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,251,987

 

 

 

-

 

Intercompany receivables

 

 

-

 

 

 

 

 

 

 

446,088

 

 

 

-

 

 

 

548,386

 

 

 

(994,474)

 

 

-

 

Other assets

 

 

-

 

 

 

 

 

 

 

21,995

 

 

 

 

 

 

 

908,021

 

 

 

(62)

 

 

929,954

 

Total Assets

 

$(2,181,987)

 

$930,000

 

 

 

546,936

 

 

 

-

 

 

 

2,101,519

 

 

 

257,451

 

 

 

1,653,919

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total current liabilities

 

$-

 

 

$150,000

 

 

$79,535

 

 

$-

 

 

$4,260,060

 

 

$-

 

 

$4,489,595

 

Intercompany payables

 

 

-

 

 

 

-

 

 

 

44,919

 

 

 

-

 

 

 

941,377

 

 

 

(986,296)

 

 

-

 

Other liabilities

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

206,077

 

 

 

-

 

 

 

206,077

 

Total Liabilities

 

 

-

 

 

 

150,000

 

 

 

124,454

 

 

 

 -

 

 

 

5,407,514

 

 

 

(986,296)

 

 

4,695,672

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shareholders’ Deficit:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Capital stock and additional paid in capital

 

 

-

 

 

 

1,569,229

 

 

 

853,550

 

 

 

-

 

 

 

2,026,038

 

 

 

(1,339,514)

 

 

3,109,303

 

Accumulated deficit

 

 

(2,181,987)

 

 

(789,229)

 

 

(431,068)

 

 

-

 

 

 

(5,552,135)

 

 

2,583,261

 

 

 

(6,371,158)

Accumulated other comprehensive income (loss)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

131,550

 

 

 

-

 

 

 

131,550

 

Non-controlling interests

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

88,552

 

 

 

-

 

 

 

88,552

 

Total Deficit

 

 

(2,181,987)

 

 

780,000

 

 

 

422,482

 

 

 

-

 

 

 

(3,305,995)

 

 

1,243,747

 

 

 

(3,041,753)

Total Liabilities and Shareholders’ Equity

 

$(2,181,987)

 

$930,000

 

 

$546,936

 

 

$-

 

 

$2,101,519

 

 

$257,451

 

 

$1,653,919

 

Schedule of condensed consolidating statement of operations

 

 

Yubo International Biotech Limited

 

 

Platinum (Cayman Islands) and Platinum HK

 

 

Yubo

 

 

Yubo Chengdu

 

 

Yubo Beijing (VIE and

 

 

 

 

 

 

 

 

 

(Parent Company)

 

 

(Cayman Island)

 

 

 Global

 

 

(WFOE)

 

 

Subsidiaries)

 

 

Eliminations

 

 

Consolidated

 

Sales of product and services

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$3,488

 

 

$-

 

 

$3,488

 

Cost of goods and services sold

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(827)

 

 

-

 

 

 

(827)

Gross profit

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

2,661

 

 

 

-

 

 

 

2,661

 

Total operating expenses

 

 

-

 

 

 

40,000

 

 

 

3,656

 

 

 

-

 

 

 

1,371,626

 

 

 

-

 

 

 

1,415,282

 

Loss from operations

 

 

-

 

 

 

(40,000)

 

 

(3,656)

 

 

-

 

 

 

(1,368,965)

 

 

-

 

 

 

(1,412,621)

Other income (expense)

 

 

-

 

 

 

-

 

 

 

20

 

 

 

-

 

 

 

(216,305)

 

 

-

 

 

 

(216,285)

Equity in net loss of subsidiaries and variable interest entity (VIE)

 

 

(1,628,906)

 

 

-

 

 

 

 -

 

 

 

-

 

 

 

-

 

 

 

1,628,906

 

 

 

-

 

Net Loss

 

$(1,628,906)

 

$(40,000)

 

$(3,636)

 

$-

 

 

$(1,585,270)

 

$1,628,906

 

 

$(1,628,906)